Eli Lilly Pauses Clinical Trial Of COVID-19 Antibody Treatment Over ‘Potential Safety Concern’

New York Times: Eli Lilly’s Antibody Trial Is Paused Over Potential Safety Concern
“A government-sponsored clinical trial that is testing an antibody treatment for Covid-19 developed by the drugmaker Eli Lilly has been paused because of a ‘potential safety concern,’ according to emails that government officials sent on Tuesday to researchers at testing sites. The company confirmed the pause…” (Wu/Thomas, 10/13).

Additional coverage of the trial’s pause is available from The Hill, POLITICO, STAT, and Wall Street Journal.

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KFF | twitter.com/kff

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.